1 |
Ramig RF, Cross RK, and Fields BN (1977) Genome RNAs and polypeptides of reovirus serotypes 1, 2, and 3. J Virol 22, 726-733
|
2 |
Stanley NF, Dorman DC and Ponsford J (1953) Studies on the pathogenesis of a hitherto undescribed virus (hepato-encephalomyelitis) producing unusual symptoms in suckling mice. Aust J Exp Biol Med Sci 31, 147-159
DOI
|
3 |
Sabin AB. Reoviruses (1959) A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science 130, 1387-1389
DOI
|
4 |
Stanley NF (1961) Relationship of Hepatoencephalomyelitis Virus and Reoviruses. letters to Nature 189, 687
DOI
|
5 |
Ramos-Alvarez M and Sabin AB (1954) Characteristics of poliomyelitis and other enteric viruses recovered in tissue culture from healthy American children. Proc Soc Exp Biol Med 87, 655-661
DOI
|
6 |
Stoeckel J and Hay JG (2006) Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutics. Curr Opin Mol Ther 8, 249-260
|
7 |
Ramos-Alvarez M and Sabin AB (1958) Enteropathogenic viruses and bacteria. Role in summer diarrheal diseases of infancy and early childhood. Jour Amer Med Ass'n 167, 147-156
DOI
|
8 |
Jackson GG, Muldoon BL and Cooper GS (1961) Reovirus type 1 as an etiologic agent of the common cold. Jour Clin Invest 40, 1051
|
9 |
Ramos-Alvarez M and Sabin AB (1956) Intestinal viral flora of healthy children demonstrable by monkey kidney tissue culture. Amer Jour Pub Health 46, 295-299
DOI
|
10 |
Rosen L, Evans HE and Spickard A (1963) Reovirus infections in human volunteers Am J Hyg 77, 29-37
|
11 |
Vidal L, Pandha HS, Yap TA et al (2008) A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14, 7127-7137
DOI
|
12 |
Kim M (2015) Replicating poxviruses for human cancer therapy. J Microbiol 53, 209-218
DOI
|
13 |
Roberts MS, Lorence RM, Groene WS and Bamat MK (2006) Naturally oncolytic viruses. Curr Opin Mol Ther 8, 314-321
|
14 |
Wang G, Barrett JW, Stanford M et al (2006) Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A 103, 4640-4645
DOI
|
15 |
Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17, 3351-3362
DOI
|
16 |
Kim M, Williamson CT, Prudhomme J et al (2010) The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene 29, 3990-3996
DOI
|
17 |
Tyler KL (2001) Mammalian reoviruses, p. 1729-1745. In B.N. Fields, D.M. Knipe, and P.M. Howley (eds), Fields Virology, Lippincott-Raven, Philadelphia, USA
|
18 |
Harrington KJ, Karapanagiotou EM, Roulstone V et al (2010) Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 16, 3067-3077
DOI
|
19 |
Kicielinski KP, Chiocca EA, Yu JS, Gill GM, Coffey M, Markert JM (2014) Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther 22, 1056-1062
DOI
|
20 |
Le Boeuf F, Diallo JS, McCart JA et al (2010) Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18, 888-895
DOI
|
21 |
Alkassar M, Gärtner B, Roemer K et al (2011) The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo. J Neurooncol 104, 715-727
DOI
|
22 |
Forsyth P, Roldán G, George D et al (2008) A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 16, 627-632
DOI
|
23 |
Karapanagiotou EM, Roulstone V, Twigger K et al (2012) Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 18, 2080-2089
DOI
|
24 |
Galanis E, Markovic SN, Suman VJ et al (2012) Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther 20, 1998-2003
DOI
|
25 |
Morris DG, Feng X, DiFrancesco LM et al (2013) REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors. Invest New Drugs 31, 696-706
DOI
|
26 |
Minuk GY, Paul RW and Lee PW (1985) The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 16, 55-60
DOI
|
27 |
Minuk GY, Rascanin N, Paul RW, Lee PW, Buchan K and Kelly JK (1987) Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 5, 8-13
DOI
|
28 |
Kim M, Egan C, Alain T et al (2007) Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene 26, 4124-4134
DOI
|
29 |
Alain T, Kim M, Johnston RN et al (2006) The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Br J Cancer 95, 1020-1027
DOI
|
30 |
Loken SD, Norman K, Hirasawa K, Nodwell M, Lester WM and Demetrick DJ (2004) Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anticancer biotherapeutics. Cancer Biol Ther 3, 734-738
DOI
|
31 |
Kim M, Garant KA, zur Nieden NI et al (2011) Attenuated reovirus displays oncolysis with reduced host toxicity. Br J Cancer 104, 290-299
DOI
|
32 |
Kim M and Johnston RN (2014) Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy. Chinese patent No.: 200980126543.5 Date of Patent grant: July 30, 2014
|
33 |
Lolkema MP, Arkenau HT, Harrington K et al (2011) A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17, 581-588
DOI
|
34 |
Comins C, Spicer J, Protheroe A et al (2010) REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16, 5564-5572
DOI
|
35 |
Alloussi SH, Alkassar M, Urbschat S, Graf N and Gärtner B (2011) All reovirus subtypes show oncolytic potential in primary cells of human high-grade glioma. Oncol Rep 26, 645-649
|
36 |
Coschi CH and Dick FA (2012) Chromosome instability and deregulated proliferation: an unavoidable duo. Cell Mol Life Sci 69, 2009-2024
DOI
|
37 |
Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG (2013) Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13, 714-726
DOI
|
38 |
Bennette JG (1960) Isolation of a Non-pathogenic Tumour-destroying Virus from Mouse Ascites. Nature 187, 72-73
DOI
|
39 |
Nelson JB and Tarnowski GS (1960) An Oncolytic Virus recovered from Swiss Mice during Passage of an Ascites Tumour. Nature 188, 866-867
DOI
|
40 |
Bennette JG, Bush PV and Steele RD (1967) Characteristics of a newborn runt disease induced by neonatal infection with an oncolytic strain of reovirus type 3 (REO3MH). I. Pathological investigations in rats and mice. Br J Exp Pathol 48, 251-266
|
41 |
Hashiro G, Loh PC and Yau JT (1977) The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 54, 307-315
DOI
|
42 |
Duncan MR, Stanish SM and Cox DC (1978) Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 28, 444-449
|
43 |
Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW (1998) The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17, 3351-3362
DOI
|
44 |
Coffey MC, Strong JE, Forsyth PA and Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282, 1332-1334
DOI
|
45 |
Kim M, Chung YH and Johnston RN (2007) Reovirus and tumor oncolysis. J Microbiol 45, 187-192
|
46 |
Kuttler F and Mai S (2006) c-Myc, Genomic Instability and Disease. Genome Dyn 1, 171-190
|
47 |
Prochownik EV and Li Y (2007) The ever expanding role for c-Myc in promoting genomic instability. Cell Cycle 6, 1024-1029
DOI
|
48 |
Prochownik EV (2008) c-Myc: linking transformation and genomic instability. Curr Mol Med 8, 446-458
DOI
|